

# Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance

NCT06293677

---

Status	RECRUITING
Phase	Phase 4
Sponsor	Centre Hospitalier Universitaire Vaudois
Enrollment	30 participants

## Plain Language Summary

---

This study is looking at how to better dose antibiotics in children with cancer who develop a serious complication called febrile neutropenia — a fever combined with a dangerously low white blood cell count caused by chemotherapy. Some children clear drugs faster through their kidneys (augmented renal clearance), which may mean standard doses are not high enough.

**\*\*You may be eligible if...\*\***

- Your child is between 2 months and 17 years old with a cancer diagnosis
- Your child has a high likelihood of developing febrile neutropenia during the study period
- Parents (and adolescents over 14) have provided written consent

**\*\*You may NOT be eligible if...\*\***

- Your child's low white blood cell count is not related to cancer or chemotherapy
- Parents or patients (over 11) do not speak French
- You or your child refuses to participate

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (7)

- Oncologic patients aged 2 months to 17 years (older than 60 days and younger than 18 years),
- High probability of febrile neutropenia during the study period
- Written informed consent from parents and adolescents older than 14 years
- Febrile neutropenia or agranulocytosis defined as:
  - Neutropenia: absolute neutrophils  $\leq$  500 cells/ $\mu$ L or agranulocytosis: absolute neutrophils  $\leq$  100 cells/ $\mu$ L or patients expected to be neutropenic in the next 24 hours due to ongoing chemotherapy
- ... and 2 more (see full listing online)

### Exclusion (7)

- Neutropenia not related to cancer and/or chemotherapy
- Refusal to participate
- Non-French speaking parents/patients older than 11 years old
- Absence of febrile neutropenia or agranulocytosis during the study period (secondary exclusion)
- Severe renal failure (GFR  $\leq$  15 mL/min/1.73 m<sup>2</sup>)
- ... and 2 more (see full listing online)

## Locations (1 total)

---

<https://clinicaltrials.gov/study/NCT06293677>  
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Canton of Vaud, Switzerland

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).